Table of Content

1. Introduction to Rearranged During Transfection (RET) Inhibitors
1.1 Overview
1.2 Evolution of RET Inhibitors


2. Role of RET Inhibitors in Cancer


3. RET Inhibitors - Mechanism of Action


4. RET Inhibitors As Non-Small Cell Lung Cancer Therapeutics
4.1 Role of RET Inhibitors in NSCLC
4.2 Ongoing Research & Development
4.2.1 TAS0953/HM06
4.2.2 RXDX-105
4.2.3 BOS172738
4.2.4 TPX-0046


5. RET Inhibitors as Thyroid Cancer Therapeutics
5.1 Impact of RET Inhibition on Thyroid Cancer
5.2 Current Advancements & Research


6. RET Inhibitors in Colorectal Cancer
6.1 RET Gene Inhibition Influencing Colorectal Cancer
6.2 Ongoing Research & Development


7. RET Inhibitors in Other Leading Cancers
7.1 RET Inhibitors in Breast Cancer
7.2 RET Inhibitors in Liver Cancer
7.3 RET Inhibitors in Melanoma
7.4 RET Inhibitors in Hematological Cancers
7.5 RET in Gastric Cancers


8. RET Inhibitors in Combinational Therapy


9. Global RET Inhibitors Market Analysis
9.1 Overview
9.2 Current Market Scenario


10. RET Inhibitors Market Opportunities by Region
10.1 US
10.2 Europe
10.3 Japan
10.4 China


11. Retevmo (Selpercatinib)
11.1 Overview
11.2 Patents & Assignee
11.3 Dosage, Price & Sales Analysis


12. Gavreto (Pralsetinib)
12.1 Overview & Patent Information
12.2 Dosage, Price & Sales Analysis


13. Global RET Inhibitors Clinical Trials Overview
13.1 By Phase
13.2 By Status
13.3 By Region


14. Global RET Inhibitors Clinical Trials Insight By Country, Company & Indication
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-III


15. Approved & Marketed RET Inhibitors Clinical Insight
15.1 Pralsetinib (Gavreto)
15.2 Selpercatinib (RETEVMO)


16. Global RET Inhibitors Market Trends
16.1 Voroni & Inno N Collaborated to Develop Novel RET Inhibitor Candidate
16.2 Researchers Identified First Mechanism of Resistance to Retevmo
(Selpercatinib)
16.3 Helsinn Doses its Investigational RET Inhibitors in First Patient of Phase I/II
Trial
16.4 TPX-0046 - Investigational RET Inhibitor Shows Prominent Results in
Preclinical Studies


17. Global RET Inhibitors Market Dynamics - Drivers & Challenges
17.1 Global RET Inhibitor Market Drivers
17.2 Challenges for Global RET Inhibitors Market


18. Global RET Inhibitors Market - Future Outlook


19. Competitive Landscape
19.1 Boston Pharmaceuticals
19.2 Blueprint Therapeutics
19.3 Daiichi Sakyo
19.4 Eli Lilly
19.5 GSK
19.6 Helsinn
19.7 Ignyta
19.8 Inno N
19.9 LoxoOncology
19.10 Roche
19.11 Taiho
19.12 Turning Point Therapeutics